Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment.
Krejci D, Opalka P, Krejci J, Zemanova M, Zemanova P, Kultan J, Fischer O, Skrickova J, Bratova M, Cernovska M, Hrnciarik M, Coupkova H, Hurdalkova K, Barinova M, Koubkova L, Dolezal D, Safanda M, Pesek M, Svaton M. Krejci D, et al. Among authors: safanda m. Anticancer Res. 2021 May;41(5):2597-2603. doi: 10.21873/anticanres.15039. Anticancer Res. 2021. PMID: 33952489
The Role of TPS and TPA in the Diagnostics of Distant Metastases.
Kucera R, Topolcan O, Fiala O, Kinkorova J, Treska V, Zedníková I, Slouka D, Simanek V, Safanda M, Babuska V. Kucera R, et al. Among authors: safanda m. Anticancer Res. 2016 Feb;36(2):773-7. Anticancer Res. 2016. PMID: 26851038
Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis.
Haslbauer F, Petzer A, Safanda M, Tomova A, Porubska M, Bajory Z, Niepel D, Jaeger C, Bjorklof K, Kalinin D, Greil R. Haslbauer F, et al. Among authors: safanda m. Support Care Cancer. 2020 Apr;28(4):1855-1865. doi: 10.1007/s00520-019-04988-7. Epub 2019 Jul 26. Support Care Cancer. 2020. PMID: 31350601 Free PMC article.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
15 results